Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Schisanlactone E targeted drug delivery system, preparation method and application thereof

A cytosine and drug-carrying technology is applied to the cytosine targeted drug-carrying system, the preparation of the cytosine-targeted drug-carrying system, and the application field in the preparation of anti-rheumatoid arthritis drugs, which can solve the problem of affecting rheumatoid arthritis. The effect of long-term treatment of arthritis, the inability to cure rheumatoid arthritis, and the reduction of patient tolerance, etc., to achieve the effects of reducing adverse reactions, reducing the concentration of cytosine, and increasing the concentration of cytosine

Active Publication Date: 2021-06-29
HUNAN UNIV OF CHINESE MEDICINE
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Rheumatoid arthritis is currently incurable and requires long-term treatment
However, long-term drug treatment usually produces strong adverse reactions, which reduces the patient's tolerance to drugs and affects the effect of long-term treatment of rheumatoid arthritis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Schisanlactone E targeted drug delivery system, preparation method and application thereof
  • Schisanlactone E targeted drug delivery system, preparation method and application thereof
  • Schisanlactone E targeted drug delivery system, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] 1. Synthesis of Prussian blue nanoparticles:

[0038] Take 0.016g of potassium ferricyanide and 2g of PVP, successively add them to 40mL of 0.01M HCl, stir and dissolve at room temperature for 30min. The yellow clear solution obtained after dissolving was placed in an 80° C. oil bath for static reaction for 20 hours to obtain crude PB nanomaterials.

[0039] The crude PB nanomaterials were divided into 1.5mL EP tubes and centrifuged at 13500rpm for 15 minutes at 4°C. After centrifugation, discard the supernatant, combine the materials in each two tubes of EP tubes into one tube, add 1 mL of sterile deionized water, mix well, and centrifuge under the same conditions for 15 minutes, and then separate each tube The EP tube was condensed into 1 tube to obtain refined PB material.

[0040] Take 5 μL of 0.05mg / mL refined PB material, drop it on the cut silicon wafer, put it in an oven and dry it at 45°C, and take pictures with a scanning electron microscope to get the follo...

Embodiment 2

[0059] Take 20 μL of HA@RFM@PB@SE NPs (0.01mg / mL) solution and drop it on the copper grid covered with carbon film, place it under an infrared lamp and dry it at 60°C, and use a transmission electron microscope to take pictures of its shape and RFM film The status of the package. Such as Figure 5 As shown, HA@RFM@PB@SE NPs display a typical core-shell structure.

[0060] Take 100 μL each of PB NPs, PB@SE NPs, RFM@PB@SE NPs and HA@RFM@PB@SE NPs in a sample cuvette, and use Zeta potential and nanoparticle size analyzer to measure the particle size distribution and Zeta potential. structured as Figure 6 , Figure 7 shown. Such as Figure 6 As shown, the particle size peaks of PB NPs and PB@SE NPs are both around 80nm, while the particle size distribution of PB@SE NPs is wider, and there are more particles with large particle sizes, indicating that the particle size change of PB nanoparticles loaded with SE is not significant. Large, some particles have increased. The pa...

Embodiment 3

[0062] Whole blood samples from SPF grade adult SD rats were collected, centrifuged at 3000 rpm for 5 min at 4°C, and washed 5 times with PBS to obtain pure red blood cells. Mix 50 μL 4% red blood cells (v / v) with 950 μL PB NPs, PB Mix @SE NPs, RFM@PB@SE NPs, and HA@RFM@PB@SE NPs, and let the mixture stand at 37°C for 4 hours. The positive control is mixed with pure water and erythrocytes, and the erythrocytes are 100% hemolyzed after mixing. The mixture was centrifuged at 3000 rpm for 5 minutes at 4°C, and the absorbance of the supernatant at 540 nm was measured using a UV-Vis spectrophotometer. By formula: Hemolysis (%) = (I / I 0) × 100% to calculate the hemolysis rate, in the formula, Hemolysis is the hemolysis rate, I represents the absorbance of the detection sample, and I 0 Indicates the absorbance of the positive control (100% hemolysis). Each sample was repeated three times, and the average value was taken as the hemolysis rate of the sample. For the test results, s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a schisanlactone E targeted drug delivery system. The system comprises schisanlactone E, Prussian blue nanoparticles, a biomimetic membrane wrapping layer and a hyaluronic acid modification layer. The invention also discloses a preparation method of the targeted drug delivery system. The preparation method comprises the following steps: synthesizing Prussian blue nanoparticles; preparing a biomimetic membrane; preparing Prussian blue loaded schisanlactone E nanoparticles from Prussian blue nanoparticles and schisanlactone E; preparing biological biomimetic membrane coated Prussian blue loaded hemoglobin nanoparticles by using the biomimetic membrane and the Prussian blue loaded schisanlactone E nanoparticles; and performing hyaluronic acid modification to obtain the schisanlactone E targeted drug delivery system. The schisanlactone E targeted drug delivery system can accurately deliver schisanlactone E to the attack part of arthritis so as to prolong the retention time of the drug at the attack part of arthritis and ensure the safety and effectiveness of treatment. Furthermore, the invention further discloses application of the schisanlactone E targeted drug delivery system in preparation of anti-rheumatoid arthritis drugs.

Description

technical field [0001] The invention relates to targeted drugs, in particular to a targeted drug-carrying system for hemocytin. The present invention also relates to a preparation method of a hexamin targeted drug loading system and an application of the hexamin targeted drug loading system in preparing anti-rheumatoid arthritis drugs. Background technique [0002] Blood tube is a commonly used medicinal plant in Tujia nationality. It is a heterogeneous plant of the genus Schisandra in the family Schisandra, Kadsura heteroclita (Roxb) Craib, and its cane is often used as medicine. Blood tube nature and flavor are sweet, slightly pungent, warm. It has the effects of nourishing blood and activating blood, expelling wind and dampness, promoting qi and relieving pain. Tujia people often use it to treat rheumatic arthralgia, epigastric pain, menstrual pain, bone pain, rheumatoid arthritis, lumbar muscle strain, cold, postpartum wind paralysis and other diseases. Hemocytin is a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/69A61K47/61A61K31/366A61K36/57A61K36/79A61P19/02A61P29/00
CPCA61K31/366A61K47/6949A61K47/6901A61K47/61A61K36/79A61K36/57A61P19/02A61P29/00
Inventor 王炜余黄合刘斌蔡雄李斌彭彩云江星明
Owner HUNAN UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com